Sclerosis, Systemic clinical trials at UC Health
1 research study open to eligible people
open to eligible people ages 18 years and up
This study is the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study is to see how GLPG1690 is tolerated in participants with systemic sclerosis and whether there are any side effects in a long-term treatment period.